ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Bristol-Myers Discontinues Development of Hepatitis C Drug

By Nathalie Tadena Bristol-Myers Squibb Co. (BMY) said Thursday it has discontinued the development of a drug intended to treat the liver disease hepatitis C in the interest of patient safety, after a patient died and others were hospitalized. Bristol-Myers earlier this month voluntarily suspended a Phase 2 study of BMS-986094, which was formerly known as INX-189, a nucleotide polymerase inhibitor, or "nuke." The initial case of heart failure, which was the basis for halting the study, subsequently resulted in death, the company said Thursday. Bristol-Myers said it is working with the U.S. Food and Drug Administration and clinical study investigators to conduct ongoing and close follow-ups of all the study's patients. To date, nine patients have been hospitalized, including the initial patient, and two remain hospitalized. The company said the cause of these unexpected events, which involve heart and kidney toxicity, hasn't been definitively established. Bristol-Myers decision to halt the study earlier this month raised questions about the experimental drug's potential and the $2.5 billion price tag Bristol paid earlier this year to buy the company that developed it. The suspension was considered a significant setback for the drug maker--already grappling with weak sales of its Plavix anticlotting drug that lost patent protection in May--in the race to develop new hepatitis C treatments. Bristol-Myers as well as other companies such as Gilead Sciences Inc. (GILD) and Abbott Laboratories (ABT) has been looking to bring the first all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. To strengthen its hepatitis C position, Bristol-Myers in February shelled out $2.5 billion to buy Inhibitex Inc. at a whopping 163% premium. Bristol was lured primarily by Inhibitex's nuke for hepatitis C, though it did acquire other potential treatments for infectious disease in the deal. Treatments for hepatitis C are considered lucrative because the disease is prevalent in large sections of the global population. The virus, which can be transmitted sexually or through use of shared needles and at tattoo parlors, affects some 170 million people world-wide. Separately, Synergy Pharmaceuticals Inc. (SGYP) said it has agreed to acquire the assets related to shingles treatment FV-100 from Bristol-Myers. FV-100 was developed by Inhibitex. Shares were up by 10 cents to $32.25 after hours. The stock has fallen 8.8% since the start of the year. -Write to Nathalie Tadena at nathalie.tadena@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
05/21/201515:54:02Johnson & Johnson Just Stepped Up Its Hepatitis C Game
05/21/201508:59:02MannKind, Front and Center: The Best Product Doesnât Always E...
05/21/201508:05:02Following Hepatitis C, This Could Be the Next Disease Researchers...
05/20/201516:14:31Johnson & Johnson Takes On Gilead Sciences in Hep C... Again
05/20/201512:15:10What Is the S&P 500 Index?
05/20/201511:40:40Why Achillion Pharmaceuticals, Inc. Shares Are Collapsing
05/20/201510:06:02SWOT Analysis of Gilead Sciences Inc. Stock
05/20/201509:00:00Patent Challenges In Five Countries Dispute Validity Of Gilead's...
05/20/201509:00:00Patent Challenges In Five Countries Dispute Validity Of Gilead's...
05/20/201508:04:02How Celgene Stock Is Breaking All the Rules
05/19/201519:26:50Statement of Changes in Beneficial Ownership (4)
05/19/201519:26:20Statement of Changes in Beneficial Ownership (4)
05/19/201519:25:51Statement of Changes in Beneficial Ownership (4)
05/18/201519:11:02The Best Blue Chips to Own Forever
05/18/201517:00:00Gilead Sciences to Present at the UBS 2015 Global Healthcare...
05/18/201515:53:15Why Achillion Pharmaceuticals, Inc. Shares Soared Today
05/18/201508:51:31This Experimental Drug Could Finally Cure HIV
05/18/201508:05:023 Types of Risks Facing Biotech Stocks
05/17/201514:03:02Is Gilead Sciences Its Own Worst Enemy?
05/17/201507:03:023 Safe Investments in Biotech (Relatively Speaking)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad